Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation

Bibliography

• Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 2004;26:71-94
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schmidt C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-76
   PubMed Web of Science ®Google Scholar
• Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23:1993-2003
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Niederwieser D, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012;26:2462-8
   PubMed Web of Science ®Google Scholar
• Storb R, Lucarelli G, McSweeney PA, Childs RW. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. In: Broudy VC, Prchal JT, Tricot GJ, editors. Hematology 2003: American Society of Hematology Education Program Book. American Society of Hematology, Washington, DC; 2003. p. 372-97
   Google Scholar
• Bernardo ME, Piras E, Vacca A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012;120:473-6
   PubMed Web of Science ®Google Scholar
• Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 2011;117:4367-75
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400
   PubMed Web of Science ®Google Scholar
• Baron F, Sandmaier BM. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 2005;12:435-43
   PubMed Web of Science ®Google Scholar
• Servais S, Baron F, Beguin Y. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. Transfus Apher Sci 2011;44:205-10
   PubMed Web of Science ®Google Scholar
• Heimfeld S. Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation (Keynote Address). Leukemia 2003;17:856-8
   PubMed Web of Science ®Google Scholar
• Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-87
   PubMed Web of Science ®Google Scholar
• Wagner JE, Barker JN, Defor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-18
   PubMed Web of Science ®Google Scholar
• Ballen KK, Koreth J, Chen YB, et al. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012;119:1972-80
   PubMed Web of Science ®Google Scholar
• Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987;2:175-8
   PubMed Web of Science ®Google Scholar
• Baron F, Schaaf-Lafontaine N, Humblet-Baron S, et al. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation 2003;76:1705-13
   PubMed Web of Science ®Google Scholar
• Keever-Taylor CA, Devine SM, Soiffer RJ, et al. Characteristics of CliniMACS(R) System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant 2012;18:690-7
   PubMed Web of Science ®Google Scholar
• Shizuru JA, Bhattacharya D, Cavazzana-Calvo M. The biology of allogeneic hematopoietic cell resistance. Biol Blood Marrow Transplant 2010;16:S2-7
   PubMedGoogle Scholar
• Storb R, Yu C, Barnett T, et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999;94:1131-6
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100
   PubMed Web of Science ®Google Scholar
• Suarez-Alvarez B, Lopez-Vazquez A, Lopez-Larrea C. Mobilization and homing of hematopoietic stem cells. Adv Exp Med Biol 2012;741:152-70
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008;15:49-58
   PubMed Web of Science ®Google Scholar
• Robinson SN, Simmons PJ, Thomas MW, et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol 2012;40:445-56
   PubMed Web of Science ®Google Scholar
• Sorrentino BP. Clinical strategies for expansion of haematopoietic stem cells (Review). Nat Rev Immunol 2004;4:878-88
   PubMed Web of Science ®Google Scholar
• Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol 2010;10:201-9
   PubMed Web of Science ®Google Scholar
• Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006;20:1690-700
   PubMed Web of Science ®Google Scholar
• Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004;104:2254-62
   PubMed Web of Science ®Google Scholar
• Baron F, Petersdorf EW, Gooley T, et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant 2009;15:580-8
   Google Scholar
• Breuer S, Preuner S, Fritsch G, et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia 2012;26:509-19
   PubMed Web of Science ®Google Scholar
• Mattsson J, Ringden O, Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14:165-70
   PubMed Web of Science ®Google Scholar
• Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001;345:1794-800
   PubMed Web of Science ®Google Scholar
• Rocha V, Broxmeyer HE. New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant 2010;16:S126-32
   PubMedGoogle Scholar
• Martin PJ, Hansen JA, Torok-Storb B, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988;3:445-56
   PubMed Web of Science ®Google Scholar
• Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006;12:454-65
   PubMed Web of Science ®Google Scholar
• de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:865-72
   PubMed Web of Science ®Google Scholar
• Baron F, Maris MB, Storer BE, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2005;11:272-9
   PubMed Web of Science ®Google Scholar
• Baron F, Maris MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005;19:822-8
   PubMed Web of Science ®Google Scholar
• Spellman S, Bray R, Rosen-Bronson S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010;115:2704-8
   PubMed Web of Science ®Google Scholar
• Rondon G, Saliba RM, Khouri I, et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 2008;14:859-66
   PubMed Web of Science ®Google Scholar
• Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of the 4 randomized studies. Blood 2001;98:3569-74
   PubMed Web of Science ®Google Scholar
• Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-60
   PubMed Web of Science ®Google Scholar
• Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89:3048-54
   PubMed Web of Science ®Google Scholar
• Sorror ML, Leisenring W, Mielcarek M, et al. Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 Gray total body irradiation. Transplantation 2008;85:1023-9
   PubMed Web of Science ®Google Scholar
• Diaconescu R, Little M-T, Leisenring W, et al. What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation? Biol Blood Marrow Transplant 2005;11:335-44
   PubMed Web of Science ®Google Scholar
• Baron F, Sandmaier BM, Storer BE, et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 2007;13:1041-8
   PubMed Web of Science ®Google Scholar
• Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-6
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:1186-93
   PubMed Web of Science ®Google Scholar
• Colson YL, Wren SM, Schuchert MJ, et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol 1995;155:4179-88
   PubMed Web of Science ®Google Scholar
• O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002;8:377-86
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011;118:282-8
   PubMed Web of Science ®Google Scholar
• Robin M, Sanz GF, Ionescu I, et al. Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. Leukemia 2011;25:75-81
   PubMed Web of Science ®Google Scholar
• Zaucha JM, Zellmer E, Georges G, et al. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant 2001;7:613-19
   PubMed Web of Science ®Google Scholar
• Bachar-Lustig E, Rachamim N, Li HW, et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268-73
   PubMed Web of Science ®Google Scholar
• Federmann B, Hagele M, Pfeiffer M, et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 2011;25:121-9
   PubMed Web of Science ®Google Scholar
• Barker JN, Weisdorf DJ, Defor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-7
   PubMed Web of Science ®Google Scholar
• Mehta J, Powles R, Singhal S, et al. Outcome of autologous rescue after failed engraftment of allogeneic marrow. Bone Marrow Transplant 1996;17:213-17
   PubMed Web of Science ®Google Scholar
• Bolger GB, Sullivan KM, Storb R, et al. Second marrow infusion for poor graft function after allogeneic marrow transplantation. Bone Marrow Transplant 1986;1:21-30
   PubMed Web of Science ®Google Scholar
• Remberger M, Ringden O, Ljungman P, et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;22:73-8
   PubMed Web of Science ®Google Scholar
• Larocca A, Piaggio G, Podesta M, et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 2006;91:935-40
   PubMed Web of Science ®Google Scholar
• Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004;103:790-5
   PubMed Web of Science ®Google Scholar
• Mohamedbhai SG, Edwards N, Morris EC, et al. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure. Br J Haematol 2012;156:516-22
   PubMed Web of Science ®Google Scholar
• Baron F, Sandmaier BM, Zellmer E, et al. Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation. Biol Blood Marrow Transplant 2006;12:813-17
   PubMed Web of Science ®Google Scholar
• Schriber J, Agovi MA, Ho V, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 2010;16:1099-106
   PubMed Web of Science ®Google Scholar
• Chewning JH, Castro-Malaspina H, Jakubowski A, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 2007;13:1313-23
   PubMed Web of Science ®Google Scholar
• Waki F, Masuoka K, Fukuda T, et al. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transplant 2011;17:841-51
   PubMed Web of Science ®Google Scholar
• Fuji S, Nakamura F, Hatanaka K, et al. Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2012;18:1407-14
   PubMed Web of Science ®Google Scholar
• Guardiola P, Kuentz M, Garban F, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 2000;111:292-302
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303:1617-24
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47:906-23
   PubMed Web of Science ®Google Scholar
• Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood 2012;120:1545-51
   PubMed Web of Science ®Google Scholar
• Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009;15:564-73
   PubMed Web of Science ®Google Scholar
• Straathof KC, Rao K, Eyrich M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009;374:912-20
   PubMed Web of Science ®Google Scholar
• Pagel JM, Gooley TA, Rajendran J, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009;114:5444-53
   PubMed Web of Science ®Google Scholar
• Chen Y, Kornblit B, Hamlin DK, et al. Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 2012;119:1130-8
   PubMed Web of Science ®Google Scholar
• Czechowicz A, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007;318:1296-9
   PubMed Web of Science ®Google Scholar
• Kang Y, Chen BJ, DeOliveira D, et al. Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS ONE 2010;5:e11316
   PubMed Web of Science ®Google Scholar
• Hoggatt J, Singh P, Sampath J, Pelus LM. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009;113:5444-55
   PubMed Web of Science ®Google Scholar
• Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008;9:831-9
   PubMed Web of Science ®Google Scholar
• Delaney C, Bollard CM, Shpall EJ. Cord blood graft engineering. Biol Blood Marrow Transplant 2012
   Google Scholar
• Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013;121(5):752-8
   PubMed Web of Science ®Google Scholar
• Karanu FN, Murdoch B, Gallacher L, et al. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med 2000;192:1365-72
   PubMed Web of Science ®Google Scholar
• Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010;16:232-6
   PubMed Web of Science ®Google Scholar
• de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012;367:2305-15
   PubMed Web of Science ®Google Scholar
• Goessling W, Allen RS, Guan X, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011;8:445-58
   PubMed Web of Science ®Google Scholar
• de Lima M, McMannis J, Gee A, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant 2008;41:771-8
   PubMed Web of Science ®Google Scholar
• Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol 2012;40:342-55
   PubMed Web of Science ®Google Scholar
• Bautista G, Cabrera JR, Regidor C, et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant 2009;43:365-73
   PubMed Web of Science ®Google Scholar
• Handgretinger R. Negative depletion of CD3(+) and TcRalphabeta(+) T cells. Curr Opin Hematol 2012;19:434-9
   PubMed Web of Science ®Google Scholar
• Panse JP, Storb R, Storer B, et al. Prolonged allogeneic marrow engraftment following nonmyeloablative conditioning using 100 cGy total body irradiation and pentostatin before and pharmocological immunosuppression after transplantation. Transplantation 2005;80:1518-21
   PubMed Web of Science ®Google Scholar
• Mariotti J, Taylor J, Massey PR, et al. The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. Biol Blood Marrow Transplant 2011;17:620-31
   PubMed Web of Science ®Google Scholar
• Danylesko I, Shimoni A, Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplant 2012;47:5-14
   PubMed Web of Science ®Google Scholar
• Veys P. Reduced intensity transplantation for primary immunodeficiency disorders. Pediatry Rep 2011;3(Suppl 2):e11
   Google Scholar
• Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007;25:690-7
   PubMed Web of Science ®Google Scholar
• Barsoukov AA, Moore PF, Storb R, et al. The use of an anti-TCRαβ monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation 1999;67:1329-35
   PubMed Web of Science ®Google Scholar
• Bethge WA, Wilbur DS, Storb R, et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003;101:5068-75
   PubMed Web of Science ®Google Scholar
• Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992;257:792-5
   PubMed Web of Science ®Google Scholar
• Storb R, Yu C, Zaucha JM, et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999;94:2523-9
   PubMed Web of Science ®Google Scholar
• Chen Y, Fukuda T, Thakar MS, et al. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy 2011;13:1269-80
   Web of Science ®Google Scholar
• Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000;6:464-9
   PubMed Web of Science ®Google Scholar
• Jochum C, Beste M, Zellmer E, et al. CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation. Biol Blood Marrow Transplant 2007;13:164-71
   PubMed Web of Science ®Google Scholar
• Buhler L, Alwayn IP, Appel JZ III, et al. Anti-CD154 monoclonal antibody and thromboembolism. Transplantation 2001;71:491
   PubMed Web of Science ®Google Scholar
• Lambert JF, Colvin GA, Zhong S, et al. H2-mismatched transplantation with repetitive cell infusions and CD40 ligand antibody infusions without myeloablation. Br J Haematol 2002;119:155-63
   PubMed Web of Science ®Google Scholar
• Kean LS, Hamby K, Koehn B, et al. NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation. Am J Transplant 2006;6:292-304
   PubMed Web of Science ®Google Scholar
• Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 2012;12:325-38
   PubMed Web of Science ®Google Scholar
• Hogan WJ, Little M-T, Zellmer E, et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant 2003;9:489-95
   PubMed Web of Science ®Google Scholar
• Ho VT, Aldridge J, Kim HT, et al. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009;15:844-50
   PubMed Web of Science ®Google Scholar
• Junghanss C, Rathsack S, Wacke R, et al. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012;18:1061-8
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R. Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol Blood Marrow Transplant 2012;18:822-40
   PubMed Web of Science ®Google Scholar
• Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010;16:838-47
   PubMed Web of Science ®Google Scholar
• Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007;110:2764-7
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Ball LM, Cometa AM, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2011;46:200-7
   PubMed Web of Science ®Google Scholar
• Lee WS, Suzuki Y, Graves SS, et al. Canine bone marrow derived mesenchymal stromal cells suppress allo-reactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation. Biol Blood Marrow Transplant 2011;17:465-75
   PubMed Web of Science ®Google Scholar
• Ophir E, Reisner Y. The use of donor-derived veto cells in hematopoietic stem cell transplantation. Front Immunol 2012;3:93
   Google Scholar
• Cardenas PA, Huang Y, Ildstad ST. The role of pDC, recipient T(reg) and donor T(reg) in HSC engraftment: mechanisms of facilitation. Chimerism 2011;2:65-70
   PubMedGoogle Scholar
• Taylor PA, Ehrhardt MJ, Roforth MM, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 2007;109:1307-15
   PubMed Web of Science ®Google Scholar
• Focosi D, Zucca A, Scatena F. The role of anti-HLA antibodies in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1585-8
   PubMed Web of Science ®Google Scholar
• Takanashi M, Atsuta Y, Fujiwara K, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010;116:2839-46
   PubMed Web of Science ®Google Scholar
• Leffell MS, Cao K, Coppage M, et al. Incidence of humoral sensitization in HLA partially mismatched hematopoietic stem cell transplantation. Tissue Antigens 2009;74:494-8
   PubMed Web of Science ®Google Scholar
• Storb R, Raff RF, Appelbaum FR, et al. What radiation dose for DLA-identical canine marrow grafts? Blood 1988;72:1300-4
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Storb R. Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' hematopoietic cell transplantation. 3rd edition. Blackwell Publishing Ltd, Oxford, UK; 2004. p. 1164-76
   Google Scholar
• Yu C, Storb R, Mathey B, et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995;86:4376-81
   PubMed Web of Science ®Google Scholar
• Xun C-Q, Little M-T, Zellmer E, et al. What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation? Transplantation 2002;73:310-13
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Review). Mol Ther 2006;13:26-41
   PubMed Web of Science ®Google Scholar